CSS
PTCT icon

Cubist Systematic Strategies’s PTC Therapeutics PTCT Stock Holding History

Cubist Systematic Strategies’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,641
Closed -$2.23M – 3439
2025
Q2 		$2.23M Buy
+45,641
New +$2.17M 0.01% 1511
2025
Q1 		– Sell
-141,410
Closed -$6.38M – 3392
2024
Q4 		$6.38M Buy
141,410
+80,736
+133% +$3.46M 0.04% 692
2024
Q3 		$2.25M Sell
60,674
-417,767
-87% -$14M 0.01% 1357
2024
Q2 		$14.6M Buy
478,441
+121,139
+34% +$3.92M 0.1% 246
2024
Q1 		$10.4M Buy
357,302
+140,894
+65% +$3.95M 0.06% 509
2023
Q4 		$5.96M Buy
+216,408
New +$4.95M 0.04% 763
2023
Q3 		– Sell
-36,800
Closed -$1.5M – 3812
2023
Q2 		$1.5M Buy
36,800
+22,278
+153% +$1.09M 0.01% 1711
2023
Q1 		$703K Sell
14,522
-11,815
-45% -$540K ﹤0.01% 2450
2022
Q4 		$1.01M Sell
26,337
-91,273
-78% -$3.79M 0.01% 2437
2022
Q3 		$5.9M Buy
117,610
+90,540
+334% +$4.44M 0.03% 916
2022
Q2 		$1.08M Sell
27,070
-2,589
-9% -$90.8K 0.01% 2419
2022
Q1 		$1.11M Buy
29,659
+12,400
+72% +$478K 0.01% 1955
2021
Q4 		$687K Sell
17,259
-21,407
-55% -$819K 0.01% 2207
2021
Q3 		$1.44M Sell
38,666
-12,743
-25% -$523K 0.02% 1255
2021
Q2 		$2.17M Buy
51,409
+18,137
+55% +$777K 0.02% 1028
2021
Q1 		$1.57M Sell
33,272
-11,398
-26% -$677K 0.02% 1216
2020
Q4 		$2.73M Buy
44,670
+24,765
+124% +$1.46M 0.04% 769
2020
Q3 		$931K Buy
19,905
+19,005
+2,112% +$936K 0.01% 1381
2020
Q2 		$46K Buy
900
+823
+1,069% +$40.4K ﹤0.01% 2276
2020
Q1 		$3K Sell
77
-27,023
-100% -$1.36M ﹤0.01% 2108
2019
Q4 		$1.3M Buy
27,100
+22,462
+484% +$954K 0.02% 993
2019
Q3 		$157K Sell
4,638
-43,635
-90% -$1.9M ﹤0.01% 1847
2019
Q2 		$2.17M Buy
48,273
+45,473
+1,624% +$1.8M 0.04% 641
2019
Q1 		$105K Buy
2,800
+1,000
+56% +$33.6K ﹤0.01% 1987
2018
Q4 		$62K Sell
1,800
-288
-14% -$10.4K ﹤0.01% 1843
2018
Q3 		$98K Buy
+2,088
New +$86.4K 0.01% 1609
2018
Q2 		– Sell
-16,306
Closed -$441K – 1991
2018
Q1 		$441K Buy
+16,306
New +$413K 0.03% 889
2017
Q4 		– Sell
-4,662
Closed -$93K – 2061
2017
Q3 		$93K Buy
4,662
+3,294
+241% +$64.5K 0.01% 1644
2017
Q2 		$25K Buy
+1,368
New +$18.4K ﹤0.01% 1595
2017
Q1 		– Sell
-14,689
Closed -$160K – 1808
2016
Q4 		$160K Sell
14,689
-355
-2% -$3.72K 0.01% 1344
2016
Q3 		$211K Buy
+15,044
New +$122K 0.01% 1224
2015
Q4 		– Sell
-3,115
Closed -$83K – 1904
2015
Q3 		$83K Buy
3,115
+1,035
+50% +$44.3K ﹤0.01% 1659
2015
Q2 		$100K Sell
2,080
-3,817
-65% -$223K ﹤0.01% 1619
2015
Q1 		$359K Buy
5,897
+4,397
+293% +$268K 0.02% 1147
2014
Q4 		$78K Buy
1,500
+500
+50% +$22K ﹤0.01% 1734
2014
Q3 		$44K Buy
+1,000
New +$31.3K ﹤0.01% 1643

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's PTCT Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 45,641 shares — an estimated $2.23M sold.

Cubist Systematic Strategies first reported a position in PTCT in Q3 2014 and held it in 36 quarters. The position peaked at $14.6M in Q2 2024. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 45,641 PTC Therapeutics shares in Q3 2025, an estimated $2.23M.
  • Cubist Systematic Strategies first reported a position in PTC Therapeutics in Q3 2014 and held it in 36 quarters.
  • Cubist Systematic Strategies's PTC Therapeutics position peaked at $14.6M in Q2 2024.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.